nasdaqsny
Shares of Sanofi were up 10.20% the week ended March 24, while Regeneron finished with a gain of 9.68%, following promising news about the company’s jointly developed medication Dupixent.Clinical trial results showed the drug reduced severe flare-ups of COPD at a far better rate than a placebo.There are currently no equivalent treatments for COPD, meaning the drug has blockbuster potential, once approved.Analysts expect Dupixent sales to total $20 billion by the end of the decade.Wall Street has boosted price targets for both companies.5 stocks we like better than SanofiQ4 2022 hedge fund lett...
ValueWalk
As we’re seeing with the Russia-Ukraine war, getting world leaders to agree on diplomatic policy is a major challenge. On a far less critical scale, the same goes for sell-side research firms when it comes to projecting a company’s earnings prospects. Opinions and EPS projections often vary widely based on revenue projections and cost assumptions. Q4 2021 hedge fund letters, conferences and more Even with a binary decision like calling a stock a buy or sell, Wall Street analysts have a difficult time reaching the same conclusion. Data from Refinitiv’s I/B/E/S estimates includes one through fiv...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら